Cureon A/S and Pantheco A/S, two Danish firms that specialize in developing antisense drugs based on DNA analogue chemistry, disclosed plans to merge in a stock-based transaction that would create a "nucleic acid powerhouse" focusing initially on cancer therapy. (BioWorld International) Read More
